Search Results

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).

• Authors : Lane WS; Mountain Diabetes and Endocrine Centre, Asheville, NC .; Favaro E

Subjects: Insulin Aspart*/Insulin Aspart*/Insulin Aspart*/administration & dosage ; Insulin Aspart*/Insulin Aspart*/Insulin Aspart*/adverse effects ; Insulin, Long-Acting*/Insulin, Long-Acting*/Insulin, Long-Acting*/administration & dosage

• Source: Diabetes care [Diabetes Care] 2020 Aug; Vol. 43 (8), pp. 1710-1716. Date of Electronic Publication: 2020 Mar 24.Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print-Electronic Cited Medium:

Record details

Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.

• Authors : Guo L; Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1, Dahua Road, Dongcheng District, Beijing, 100730, China. .

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*adverse effects ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*chemically induced ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*adverse effects

• Source: Scientific reports [Sci Rep] 2021 Feb 18; Vol. 11 (1), pp. 4131. Date of Electronic Publication: 2021 Feb 18.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.

• Authors : Guo L; Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Beijing, China.; Chen L

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*administration & dosage ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*administration & dosage

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Dec; Vol. 20 (12), pp. 2740-2747. Date of Electronic Publication: 2018 Aug 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.

• Authors : Linjawi S; Coffs Endocrine and Diabetes Services, Coffs Harbour, New South Wales, Australia. Electronic address: .; Sothiratnam R

Subjects: Biphasic Insulins/Biphasic Insulins/Biphasic Insulins/*administration & dosage ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*administration & dosage

• Source: Primary care diabetes [Prim Care Diabetes] 2015 Oct; Vol. 9 (5), pp. 370-6. Date of Electronic Publication: 2014 Dec 03.Publisher: Elsevier Country of Publication: England NLM ID: 101463825 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0210

Record details

Effects of insulin analogs as an add-on to metformin on cutaneous microcirculation in type 2 diabetic patients.

• Authors : Fysekidis M; AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cité, Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, Bondy, France; Sorbonne Paris Cité, UMR U1153 Inserm/U1125 Inra/Cnam/Université Paris 13, Bobigny, France.

Subjects: Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Endothelium, Vascular/Endothelium, Vascular/Endothelium, Vascular/*drug effects

• Source: Microvascular research [Microvasc Res] 2018 Mar; Vol. 116, pp. 6-14. Date of Electronic Publication: 2017 Sep 24.Publisher: Academic Press Country of Publication: United States NLM ID: 0165035 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

门冬胰岛素、地特胰岛素、甘精胰岛素分别联合二甲双胍 对糖尿病孕妇妊娠结局的影响.

• Authors : 何文慧¹ ; 刘风伟¹; 秦业强¹

Subjects: *INSULIN aspart; *GESTATIONAL diabetes; *INSULIN

• Source: Progress in Modern Biomedicine. 2023, Vol. 23 Issue 23, p4584-4589. 6p.

Record details

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

• Authors : Ludvik, Bernhard (AUTHOR); Giorgino, Francesco (AUTHOR); Jódar, Esteban (AUTHOR)

Subjects: INSULIN aspart; ELI Lilly & Co.; SODIUM-glucose cotransporter 2 inhibitors

• Source: Lancet. Aug2021, Vol. 398 Issue 10300, p583-598. 16p.

Record details

Metformin: a 60-year odyssey with the journey still continuing – a personal commentary from Professor Ian Campbell.

• Authors : Campbell, Ian W.¹ (AUTHOR)

Subjects: *METFORMIN; *INSULIN aspart

• Source: Current Medical Research & Opinion. Jan 2022, Vol. 38 Issue 1, p55-58. 4p.

Record details

Metformin/risperidone: Gastrointestinal disorder and hyperglycaemia: case report.

Subjects: *METFORMIN; *INSULIN aspart; *HYPERGLYCEMIA

• Source: Reactions Weekly. Aug2023, Vol. 1969 Issue 1, p231-231. 1p.

Record details

Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial.

• Authors : Yao, Jun¹ (AUTHOR); Guo, Xiaohui¹ (AUTHOR) ; Sun, Li² (AUTHOR)

Subjects: *INSULIN aspart; *METFORMIN; *DIABETESCHINA

• Source: Current Medical Research & Opinion. Nov2022, Vol. 38 Issue 11, p1797-1806. 10p.

Record details